KRAS-associated microRNAs in colorectal cancer

12Citations
Citations of this article
29Readers
Mendeley users who have this article in their library.

Abstract

Colorectal cancer (CRC) is one of the leading causes of cancer-related death worldwide. Despite progress in treatment of cancers, CRC with KRAS mutations are resistant towards anti-EGFR treatment. MicroRNAs have been discovered in an exponential manner within the last few years and have been known to exert either an onco-miRNA or tumor suppressive effect. Here, the various roles of microRNAs involved in the initiation and progression of KRAS-regulated CRC are summarized. A thorough understanding of the roles and functions of the plethora of microRNAs associated with KRAS in CRC will grant insights into the provision of other potential therapeutic targets as well as treatment. MicroRNAs may also serve as potential molecular classifier or early detection biomarkers for future treatment and diagnosis of CRC.

Cite

CITATION STYLE

APA

Ibrahim, H., & Lim, Y. C. (2020, July 9). KRAS-associated microRNAs in colorectal cancer. Oncology Reviews. Page Press Publications. https://doi.org/10.4081/ONCOL.2020.454

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free